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Abstract
Hepatocellular carcinoma (HCC) is the most common primary liver malignancy with cir-
rhosis preceding its development in most cases. Surgical resection remains the primary 
therapeutic option despite the recent emergence of locoregional therapies. Novel surgical 
techniques are being proposed to overcome the limitations of traditional anatomical open 
liver resection. Laparoscopic resection is a safe and effective alternative to open liver 
resection, especially for left lateral or peripheral segment tumors. It is associated with 
less postoperative morbidity, intraoperative blood loss, and medial hospital stay with no 
difference in oncological outcomes. Robotic-assisted liver resection overcomes the techni-
cally difficult resection of tumors located at the posterosuperior segments with similar 
outcomes to laparoscopic resection. Associated liver partition and portal vein ligation for 
staged hepatectomy (ALPPS) procedure allows resection in patients with HCC, and asso-
ciated major vascular resection or small future liver remnant (FLR) with long-term results 
yet to be announced. For patients with small solitary tumors or poor liver function, non-
anatomical liver resection is a feasible therapeutic option due to minimal postoperative 
morbidity and similar oncological results of anatomical resection.
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1. Introduction
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third lead-
ing cause of cancer-related deaths worldwide [1]. Cirrhotic patients have the highest risk of 
developing HCC [2]. Numerous factors contribute to cirrhosis which precedes HCC develop-
ment, including viral hepatitis, heavy drinking, and aflatoxin exposure. Hepatitis C epidemic 
in the Western world and Hepatitis B epidemic in China have attributed to the incidence of 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
HCC [3]. However, HCC has a dismal prognosis, mainly due to the early recurrence; about 
40% of patients that have undergone hepatectomy develop recurrence within the first year 
after surgery [2].
Although liver transplantation is considered as the ideal treatment, hepatic resection remains 
the only curative method of therapy for HCC. Other methods of potentially curative therapy 
are radiofrequency ablation (RFA), microwave ablation (MWA), high power focused ultra-
sound ablation (HIFU), and transarterial chemoembolization (TACE) [4, 5].
Novel surgical techniques are being proposed to overcome the limitations of traditional ana-
tomical open liver resection. Laparoscopic and robotic resection as well as nonanatomical 
resection and ALPPS procedure have emerged as new and effective ways of surgical therapy 
for HCC.
The aim of this chapter is to analyze the aforementioned novel surgical techniques in the 
management of HCC and present the results from the relevant studies.
2. Laparoscopic liver resection for HCC
Laparoscopic surgery has become widely accepted as a feasible alternative to traditional open 
surgery for many surgical indications. The first laparoscopic hepatectomy was performed in 
1992, for a benign tumor by Gagner et al. [6], and the first laparoscopic resection for HCC was 
reported in 1995 [7].
The liver presents many and significant technical challenges for minimally invasive tech-
niques. Its mobilization is difficult, the space is limited, its vascular and biliary anatomy is 
complex and the parenchyma is fragile, friable and often fibrotic or cirrhotic [8]. Nevertheless, 
numerous studies have already shown the feasibility and safety of wedge resections, single-
segment resections, and left lateral sectionectomies [9, 10].
The first international consensus conference on laparoscopic liver resection (LLR) was held 
in Louisville in 2008. It was suggested that the best indications for laparoscopic excision 
were solitary lesions less than 5 cm, located in the anterior segments. Also, the resection 
should be far from the hepatic hilum and the vena cava [11]. The second international 
consensus was held in Morioka, Japan in 2014, stating that anatomical resection for HCC 
is standard of care procedure, but the laparoscopic version needs to be standardized to 
increase propagation [12].
There are many reasons why laparoscopic major hepatectomy has not been widely accepted 
and performed yet. There are technical difficulties related to liver mobilization, vascular con-
trol, inability for manual palpation, access to posterosuperior liver segments, and intraopera-
tive hazards such as gas embolism, massive bleeding, and bile duct injury [13, 14].
The benefits of laparoscopic surgery, though, have long been proven. Early postoperative 
ambulation, decreased respiratory complications, minimization of blood loss, minimal abdom-
inal trauma, and less postoperative pain are some of the accepted benefits of laparoscopic 
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surgery. For cirrhotic patients with HCC, the minimization of the surgical incision and the 
subsequent preservation of the abdominal wall circulation and lymphatic flow explains the 
decrease in postoperative liver failure and ascites formation [15].
The last decade, several meta-analyses of laparoscopic vs. open resection for HCC have been 
published [16–23]. These meta-analyses have analyzed and compared the results of many 
nonrandomized control trials and case-matched studies. Three categories of outcomes were 
used to compare the two operative techniques:
a. Operative outcomes, such as operative time, operative blood loss, and number of patients 
that needed transfusion.
b. Postoperative outcomes, such as morbidity, mortality, and hospital stay.
c. Oncologic results, such as pathologic resection margins, incidence of port-site recurrence, 
disease-free survival (DFS), and overall survival (OS).
Jiang et al. [16] reported the superiority of laparoscopic liver resection (LLR) concerning 
the reduced intraoperative blood loss and blood transfusion, the expansion of the patho-
logic resection margins, the increase of R0 resection, and the shorter length of hospital stay. 
Laparoscopic resection has similar OS, DFS, and recurrence rate as open liver resection (OLR).
Sotiropoulos et al. [17], in a recent meta-analysis of 44 studies, showed that laparoscopic 
resection is superior to open resection in terms of resection margin and R0 resection. It is 
possible that this difference in resection margin and R0 excision is due to the smaller size of 
tumors resected in the laparoscopic group. It was confirmed that the laparoscopic technique 
is strongly associated with less blood loss, fewer blood transfusions, less postoperative pain, 
faster recovery, and shorter hospital stay. Operative time and tumor recurrence were not 
statistically different between LLR and OLR as well as the long-term oncological results such 
as OS and DFS. These results confirm those of previous authors [15, 18, 21, 22]. Hand-assisted 
laparoscopic or laparoscopy-assisted resections (hybrid group) gain statistical advantage over 
the OLR group concerning the negative resection margin width and influence the results in 
favor of LLR. They, however, showed no difference as to the OS and 30-day mortality com-
pared to the OLR group.
The main concerns about LLR are the inadequate tumor resection margins and the potential 
risk of port-site recurrence. Tumor recurrence is the main cause of death in patients with 
HCC. The adequate tumor-free margin is a prognostic indicator of HCC [23]. Due to the lack 
of tactile sensation in laparoscopic surgery, the tumor location is sometimes difficult to deter-
mine. Intraoperative ultrasonography is a useful tool for precise identification of lesions and 
its borders [24, 25]. Another concerning factor is the risk of tumor peritoneal dissemination 
and port-site metastases [26, 27]. Interestingly, there has not been any evidence so far of tumor 
peritoneal dissemination or port-site metastases [20, 22]. The use of a plastic bag to remove 
the specimen can help to prevent this complication.
Concern has also been raised about the safety of laparoscopic techniques in cirrhotic patients. 
A plethora of patients with HCC also suffer from cirrhosis. Portal hypertension is a major risk 
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factor for the development of postoperative decompensation [28, 29]. The benefits of LLR can 
be attributed to the preservation of the abdominal wall collateral circulation and the preserva-
tion of the round ligament which may contain significant collateral veins [18]. In a study by 
Tranchart et al., LLR had lower rates of liver decompensation, with the occurrence of post-
operative liver failure and ascites ranging from 7 to 8% in LLR vs. 26–36% in OLR [30]. One 
study from Japan showed lower rates of morbidity, ascites formation, and shorter hospital 
stay following LLR with no difference in survival [31]. A recent meta-analysis presented intra-
operative and postoperative outcomes of patients with known cirrhosis undergoing resection 
for HCC, comparing results for OLR and LLR [32]. This meta-analysis showed wider resec-
tion margins, reduced intraoperative blood loss and transfusion need, as well as reduced 
morbidity rates and shorter lengths of stay with the laparoscopic approach. Another study by 
Sotiropoulos et al. [33] mentioned the difference in results concerning cirrhotic patients that 
undergo LLR vs. OLR. The operative time was longer as anticipated, but the blood loss and 
morbidity had no statistical difference from the noncirrhotic group. The mortality rate was 
significantly lower in the cirrhotic subgroup when LLR was performed. Although patients 
with preserved liver function are the best candidates for LLR, cirrhotic patients benefit from 
LLR in terms of shorter hospital stay, complication rate, and long-term oncologic outcomes.
Tumor recurrence after primary HCC has been shown to be 30–70% at 5 years, limiting the 
overall survival of these patients [34, 35]. Numerous studies have been published report-
ing the results of repeat laparoscopic liver resection (RLLR) in patients with recurrent HCC 
[36–38]. A recent systematic review by Machairas et al. demonstrates RLLR as a safe and 
promising approach for the treatment of recurrent HCC, with significant benefits in terms of 
short-term outcomes with the oncologic adequacy not compromised [39].
The conversion rate has decreased from 5–15% [9, 40] to 4%, indicative of the surgeons’ grow-
ing experience, with the most common causes being bleeding and failure to progress second-
ary to difficult exposure.
Overall, LLR can facilitate a safe and feasible approach to the surgical management of 
HCC. Major laparoscopic hepatectomy still remains a technically demanding procedure 
and should only be performed by highly experienced hepatobiliary surgeons with training 
in laparoscopic surgery. Longer follow-up periods are needed for more definite conclusions 
about the survival probability of the LLR vs. the OLR groups.
3. Robotic liver resection for HCC
Robotic liver resection (RLR) has been incorporated into clinical practice with increasing 
frequency since 2003 when the first report of a robotic liver resection was published by 
Giulianotti et al. [41].
Robotic technology was developed to overcome the technical difficulties of laparoscopic sur-
gery; precision of movement, three-dimensional vision, magnification of the operative field, 
motion scaling, tremor filtering, and seven degrees of movement mimicking the human hand 
provide steady and careful dissection as well as prompt and precise endosuturing in case of 
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intraoperative bleeding. A major advantage of the robotic technology in liver surgery is the dis-
section of the hilum and the hepatocaval dissection in right hepatectomy [42] as well as the pos-
sibility of biliary reconstruction due to the microsuturing capacity of the robotic system [43].
All published liver resections were performed using the da Vinci Surgical System (Intuitive 
Surgical Inc., Sunnyvale, CA USA). The major disadvantage of robotic surgery is the high 
cost due to the longer operating time and the instruments required, in spite of the similar 
hospitalization costs [44]. The purchase and maintenance costs are significant, and that is the 
reason for the limited incorporation of the robotic system in many facilities.
A large series by Tsung et al. [45] compared RLR to LLR and with the exception of opera-
tive time, and they found no significant differences comparing operative and postoperative 
results of RLR and LLR. The R0 status did not change, and the oncologic margin was not com-
promised. It must be highlighted that using a minimally invasive technique, a greater percent-
age of minor and major hepatectomies was completed; 93% of RLRs were accomplished in a 
purely minimally invasive manner compared with 49.1% performed laparoscopically.
Chen et al. [46] compared RLR with OLR for HCC providing superior short-term outcomes 
for RLR (shorter length of stay and decreased need for patient-controlled analgesia) and simi-
lar long-term outcomes (DFS and OS) despite longer operative times for RLR. A substantial 
proportion of patients suffered from cirrhosis and half of patients underwent major hepatec-
tomy. They reported a DFS in 1 year of 91.5% with the RLR, whereas DFS was 79.2%. Overall 
survival in 1 and 3 years did not differ between the two groups. The authors reported that the 
patients treated with RLR had significantly wider surgical margins compared with OLR. This 
matched comparison offers support for further RLR in patients with HCC, performed by 
experienced surgeons.
Another study by Lai et al. [47] presented the results of RLR vs. LLR for HCC. Robotic group 
had longer mean operating time (207.4 vs. 134.2 min). Both groups had similar blood loss 
(334.6 vs. 336 ml) and no difference in morbidity. Mortality rate was 0% in both groups. They 
reported a comparable 5-year DFS and 5-year OS between RLR and LLR (42 vs. 38% and 65 
vs. 48%, respectively) in patients with HCC.
Salloum et al. [48] included 14 studies in their systematic review, with HCC comprising the 
majority of the malignant cases. Mortality was 0%, and overall morbidity ranged from 0 to 
43.3%, results comparable to laparoscopy. The mean duration of LOS was similar in both 
techniques. There was no statistically significant difference between RLR and LLR concern-
ing the surgical margins or R1 resections. No clear advantages of RLR over LLR were noted; 
therefore, it is difficult to establish the true indications for RLR. Nevertheless, RLR has the 
same advantages as LLR in terms of shorter LOS and postoperative return to normal activi-
ties. Also, it seems that the learning curve for RLR is shorter than that of LLR.
The most recent systematic review from Tsilimigras et al. [49] included 31 studies with HCC 
being the leading indication among malignancies, comparing RLR to LLR or OLR. Median 
operative time was 295.5 min, EBL was 224.5 ml, conversion rate was 5.9%, and complication 
rate was 17.6% in the RLR group. The complications were graded according to the Clavien-
Dindo classification [50], with the most common complication being bile leak (2.9%). In minor 
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resections, the complication rate was 14.8% compared with the major resections, where the 
complication rate was 17%. Most of the studies show no benefit of RLR over LLR concern-
ing safety and feasibility and multicenter, and randomized, prospective trials are needed to 
validate the exact indications and benefits of RLR.
Buchs et al. [51], in a systematic review of eight studies, compared RLR to LLR with the 
majority of the malignant cases being HCC (50.3%). There were minor and major hepatec-
tomy procedures, and tumor size ranged from 8 to 120 mm. In the RLR group, there was no 
mortality, and the overall complication rate was 23.3% which fell to 19% when only post-
operative complications were considered. A reduction of the conversion rate during major 
hepatectomy was reported as well. Overall, there was no clear outcome difference between 
RLR and LLR.
Ocuin et al. [52] included 14 major series in their review with the most common indica-
tion for resection being HCC. The estimated blood loss (EBL) ranged from 50 to 413 ml 
and transfusion rates from 0 to 44%. An overall conversion rate of 7% and an overall 
complication rate of 21% were reported. No perioperative mortality was associated with 
RLR. Length of stay (LOS) varied from 4 to 12 days. One study by Ji et al. showed a shorter 
LOS following RLR than OLR (10 vs. 7 days) [53]. Most series reported a high R0 resection 
rate with no port site recurrences. Recurrence rates following RLR were similar to those 
reported for LLR [9].
In conclusion, robotic liver resection is an acceptable alternative to open surgery with 
the robotic approach allowing an increased proportion of major hepatectomies to be per-
formed in a minimally invasive manner [54]. These encouraging results should prompt the 
expansion of the robotic approach by highly specialized surgeons in experience centers 
worldwide.
4. Associating liver partition and portal vein ligation for liver 
surgery (ALPPS) for HCC
Surgical resection is the only potential curative treatment for hepatocellular carcinoma 
(HCC). In many cases, a major hepatectomy is required to achieve tumor-free surgical 
margins. However, the volume and functional reserve of the future liver remnant (FLR) 
are essential to avoid post-hepatectomy liver failure (PHLF), which is a crucial and 
important cause of morbidity and mortality after extensive liver resection [55]. In recent 
decades, some new strategies, such as portal vein embolization (PVE), portal vein ligation 
(PVL), and two-staged hepatectomy (TSH) have been developed to induce regeneration of 
FLR, minimizing the risk of PHLF and finally expanding the resectability criteria in HCC 
and generally in liver tumors [56]. Makuuchi et al. first introduced portal vein emboli-
zation into clinical practice in 1980s [57]. In 2015, a systematic review and meta-analysis 
from Pandanaboyana et al. compared PVL and PVE to assess the percentile increase of the 
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FLR, morbidity, mortality, and tumor progression [58]. This meta-analysis revealed that 
the difference in the mean percentile increase in the FLR between those two techniques 
was not statistically significant, with similar results in morbidity, mortality, and disease 
progression.
In 2000s, Adam et al. first described the two-staged hepatectomy for liver malignancies in 
which a single surgical procedure was not possible [59]. The primary reason for the failure of 
TSH is tumor progression between two stages or an insufficient hypertrophy in FLR after the 
first stage of the procedure (portal vein occlusion).
An innovative, accelerated two-staged technique utilizing PVL and in situ split (ISS) of 
hepatic parenchyma was first described in 2012 by Schnitzbauer et al. [60]. In the same year, 
De Santibanes et al. named this procedure as ALPPS procedure (associating liver partition 
and portal vein ligation for staged hepatectomy) [61]. In 2007, ALPPS was first performed by 
chance by German surgeon Dr. Schlitt [62, 63]. In an attempt to perform an extended right 
hepatectomy for a perihilar cholangiocarcinoma, he intraoperatively realized that FLR was 
inadequate. He resected the liver adjacent to the falciform ligament after performing a left 
hepaticojejunostomy. The right portal vein was also ligated for the purpose of left lobe hyper-
trophy. Out of curiosity, on postoperative day 8, he performed a computed tomography (CT) 
scan. To his surprise, the left lateral section had extensively grown in size. He successfully 
removed the diseased liver in a second operation.
ALPPS indications are an FLR < 30% in patients with a normal liver or an FLR < 40% in 
patients with a cholestatic, steatotic or fibrotic liver [64]. Therefore, ALPPS can be performed 
for marginally resectable or locally advanced tumors with an inadequate FLR. This technique 
constitutes a surgical strategy for colorectal liver metastases, hilar cholangiocarcinoma, and 
hepatocellular carcinoma [64]. On the other hand, contradictions for ALPPS procedure include 
unresectable liver metastases in the FLR, unresectable extrahepatic metastases, severe portal 
hypertension, high anesthetic risks, and a poor condition of the patient prior to this major 
operation [64]. Patients with cirrhotic liver are less capable for hypertrophy of FLR after portal 
vein obstruction (PVL or PVE) than patients with healthy liver parenchyma. Vennarecci et al. 
reported that ALPPS for HCC is safe even when performing a major hepatectomy in a cir-
rhotic liver. They also mentioned that ALPPS induces a significant increase in FLR between 
the first and the second stage of the procedure and after hepatectomy, either in healthy or 
cirrhotic patients [65].
It has been reported that postoperative morbidity and mortality after ALPPS are 16–64 and 
12–23%, respectively, with the main cause of morbidity being bile leakage and sepsis and the 
main cause of mortality being PHLF [66, 67]. In the latest systematic review and meta-analysis 
by Zhou et al., 719 patients were included, and the aim was to compare the regeneration 
efficiency, safety, and complication rates of ALPPS and TSH. The degree of FLR regeneration 
in ALPPS was significantly higher than that in TSH, and the interval of the two stages in 
ALPPS was obviously shorter than that in TSH. Bile fistulas were much more common after 
ALPPS with the reason being the liver splitting that is mandatory during this procedure. 
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Although ALPPS had lower 1-year DFS rate, no significant difference in the 90-day mortality 
rate was discovered comparing the two techniques [66]. ALPPS was associated with a higher 
completion rate, a lower probability of tumor progression during the stage interval, and a 
lower insufficient regeneration rate; these findings are similar to those of previous studies 
[56, 67, 68].
Many variations of the ALPPS technique have been recently mentioned in the literature 
with the aim of improving safety and extending indications of hepatectomy. Modifications, 
such as avoiding liver mobilization and hepatoduodenal skeletonization, seem to prevent 
tumor spreading, adhesions, overall invasiveness, and parenchymal ischemia [69–73]. 
In addition, anterior approaches, portal vein embolization (PVE) as an alternative to 
ligation, partial liver splitting, tourniquet application or ablation procedures replacing 
parenchymal transection, and laparoscopic approaches represent fundamental modifi-
cations to the original ALPPS procedure that aim to improve safety [15]. The result of 
these modifications is the reduction of morbidity and mortality in this innovative surgical 
procedure. Furthermore, prospective controlled studies are needed to confirm which of 
these modifications should be considered as a reliable and safe alternative strategy to 
classical ALPPS.
5. Anatomical vs. nonanatomical resection for HCC
The incidence of HCC continues to increase due to the dissemination of hepatitis B and C 
virus infection. Hepatic resection is the gold standard treatment for HCC [74]. Nevertheless, 
postoperative recurrence of HCC, 3 and 5 years after hepatectomy is 50–60% and 70–90%, 
respectively [75, 76].
It is known that HCC invades mainly the intrahepatic vascular system and spreads along the 
portal and hepatic vein branches, producing intrahepatic metastases [77, 78].
Since Makuuchi et al. introduced the concept of anatomical resection (AR), the advantages 
of anatomic resection for HCC have been suggested in many studies [79]. On the other 
hand, limited nonanatomic resection (NR) with a minimal safety margin may be preferred 
for patients with impaired liver function [80]. Tanaka et al. showed that microscopic vas-
cular invasion was more important than tumor size as a predictive factor for local recur-
rence [81].
Anatomical liver resection is a plausible option for patients with HCC, as HCC tends to cause 
intrahepatic metastasis through vascular invasion, and its advantages in improved OS or DFS 
for HCC patients have widely been reported [82].
In a systematic review of Cucchetti et al., AR seemed to yield improved 5-year OS and DFS 
compared to NR [83]. Zhou et al. [84] and Bigonzi et al. [85] presented significantly improved 
5-year OS with AR.
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Nonanatomic resection is recommended for patients with impaired liver function [86, 87]. The 
plausible reason is that NR can preserve as much functional liver as possible, with surgical 
curability and hepatic function equally important [87, 88]. The preservation of hepatic func-
tional reserve allows effective treatment options in HCC recurrence, which may also improve 
the long-term prognosis [87, 89].
The superiority of anatomical resection (AR) over nonanatomic resection (NR) for hepatocel-
lular carcinoma (HCC) remains controversial. Marubashi et al. reported no significant dif-
ferences in OS, DFS or recurrence within 2 years after hepatectomy between the AR and NR 
groups [90]. Likewise, Tanaka et al. reported no outstanding difference in the recurrence rates 
and OS between AR and NR patient groups; it was also stated that survival rates after recur-
rence and median survival time after recurrence were higher in the NR group compared to 
the AR group for patients with a solitary HCC confined to 1 or 2 liver segments [91]. Chen 
et al. reported in their meta-analysis that AR contributed to better DFS, but did not improve 
OS [92]. Thus, the superiority of AR over NR is still controversial. Furthermore, Yamamoto 
et al. reported that AR is associated with more perioperative risks. The same study revealed 
significantly greater intraoperative blood loss and longer postoperative hospital stay for the 
AR group [82].
In 2010, Yamashita et al. [80] published a retrospective study of 321 patients with HCC. About 
120 patients underwent limited nonanatomic resection (NR) for a single HCC < 5 cm. In non-
cirrhotic patients (n = 215), both 5-year OS and DFS rates in the AR group were consider-
ably better than those in the NR group (87 vs. 76% and 63 vs. 35%, respectively). In cirrhotic 
patients (n = 106), both 5-year OS and DFS in the AR group were worse than those in the NR 
group (48 vs. 72% and 28 vs. 43%, respectively).
According to their results, the width of the resection margin did not influence postoperative 
recurrence, and major hepatic resections did not improve patients’ survival. The main disad-
vantage of AR in comparison with NR is the limitation of a repeat resection, which would be 
the most effective treatment for recurrence, because of its disadvantageous effects on remnant 
liver function [93, 94].
In conclusion, there is a need for more, large, prospective, multicenter studies to confirm the 
data about any possible superiority of nonanatomic resection for HCC.
6. Conclusion
Hepatocellular carcinoma is a malignancy with an increasing incidence and a dismal progno-
sis. Patients are often referred to specialists in an advanced stage of the disease. Surgery is the 
primary treatment and novel surgical techniques are developed offering better perioperative 
and oncological results (Table 1). Nevertheless, prospective, randomized controlled studies 
have to be designed for the confirmation of such possible advantages of those new surgical 
techniques.
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Technique Advantages Limitations Reference
Laparoscopic resection • Early ambulation
• Decreased respiratory complications
• Minimal abdominal trauma
• Less postoperative pain
• Decrease in PHLF
• Reduced blood loss
• Shorter length of hospital stay
• Increase of R0 resection
• Technical difficulties
• Vascular control
• Difficult access to posterosuperior 
segments
• Massive bleeding
• No manual palpation
• Longer operative time
[13–17, 23, 
26, 27]
Robotic resection • Precision of movement
• 3-dimensional vision
• 7 degrees of movement
• Precise endosuturing
• Dissection of the hilum
• Biliary reconstruction
• Shorter length of stay
• High cost
• Longer operative time
• Specialized surgeons
[42–44, 46, 
54]
ALPPS • Increase in FLR
• Application to cirrhotic patients
• Marginally resectable tumors
• Locally advances tumors
• Severe portal hypertension
• High risk patients
• High rates of post-operative mor-
bidity and mortality
• Bile leakage
• Sepsis
[64–67]
Nonanatomical 
resection
• Repeat resection
• Impaired liver function
• No difference in recurrence rates
• Less intra-operative blood loss
• Cirrhotic patients
• Worse 5-year OS and DFS
• Width of resection margin
• Microscopic vascular invasion
[80, 81, 
83–85, 90, 
91, 93, 94]
Table 1. Advantages and limitations of novel surgical techniques for hepatocellular carcinoma management.
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